(
out of
61
reviews
)
Specialties
Board Certification
|
American Board of Internal Medicine (Sub: Rheumatology)
|
Patient Rating
Patients consistently praise Dr. Walsh for her expertise, thoroughness, and compassionate care, saying she listens, explains test results and treatment options clearly, and has improved their health and quality of life. Many feel involved in decision-making and confident in her recommendations. A minority noted feeling rushed, experienced awkward virtual visits with limited eye contact, or reported delays or limited follow-up communication after testing.
Generated via Patient Reviews
4.9
/5
( out of
61 reviews
)
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Internal Medicine
-Associate Professor Dermatology -Adjunct Associate Professor |
|---|---|
| Academic Divisions |
Rheumatology
|
| Board Certification |
American Board of Internal Medicine (Sub: Rheumatology)
|
Education history
| Undergraduate | Biology - Whitman College | B.A. |
|---|---|---|
| Graduate Training | Business Administration - Boise State University | M.B.A. |
| Professional Medical | Medicine - University of Utah | M.D. |
| Internship | Internal Medicine - University of Utah | Intern |
| Residency | Internal Medicine - University of Utah | Resident |
| Chief Resident | Internal Medicine - University of Utah | Chief Resident |
| Fellowship | Rheumatology - University of Utah | Fellow |
| Graduate Training | Clinical Investigation - University of Utah | M.S.C.I |
Selected Publications
Journal Article
- Rubino S, Cannon GW, Sauer BC, Rojas J, Stoddard GJ, Kunkel GA, Walsh JA, England BR, Baker JF, Braaten T (2026). Immune Checkpoint Inhibitor Related Myositis and Associated Triad Overlap Syndrome. Arthritis care & research,
- Tillett W, Gossec L, Husni ME, Morita A, Ink B, Bajracharya R, Healy P, Mørup MF, Walsh J (2026). Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies. Rheumatology advances in practice, 10(1), rkag009.
- Ogdie A, Middaugh N, Marchese M, Walsh JA, Bello N, Ngantcha M, Kronbergs A, Grace EL, Mease P (2026). Cycling to TNFi vs. Switching to IL-17Ai Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World CorEvitas PsA/SpA Registry Data. Advances in therapy,
- Karmacharya P, Crofford LJ, Byrne DW, Stephens-Shields A, Husni ME, Scher JU, Craig E, Fitzsimmons R, Reddy SM, Magrey MN, Walsh JA, Ogdie (2025). Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium. Annals of the rheumatic diseases, 84(2), 253-261.
- Allenzara A, Bush K, Husni ME, Reddy SM, Scher JU, Craig E, Koplin J, Walsh JA, Ogdie (2025). Diverse Treatment Goals in Psoriatic Arthritis: Insights from participants in the PARC cohort. Arthritis care & research, 77(8), 1007-13.
- Ogdie A, Reddy SM, Gillespie SH, Husni ME, Scher JU, Salomon-Escoto K, Kay J, Luedders BA, Curtis JR, Shields AJS, Chakravarty SD, Gong C, Walsh J (2025). Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial. Trials, 26(1), 96.
- Dubreuil M, Walsh JA, Deodhar A, Gensler LS, Curtis JR, Welby S, Pilipczuk O, Beaty S, Mørup MF, Taieb V, Anjohrin (2025). Real-World Use of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis in the United States: Persistence, Variables Associated With Persistence, and Dosing Variations. Pharmacoepidemiology and drug safety, 34(9), e70197.
- Merola JF, Welby S, Roque H, Song J, Pilipczuk O, Lu C, Walsh J (2025). Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patterns. Journal of managed care & specialty pharmacy, 31(8), 808-821.
- Singla S, Pennington SR, Hwang ST, Walsh J (2025). World Café Report From the GRAPPA 2024 Annual Meeting and Trainee Symposium: Exploring GRAPPA's Future Priorities. The Journal of rheumatology,
- Walsh JA, Saffore CD, Ye X, Patel M, Biljan A, Vora J, Truman I, Edwards M, Milligan G, Ostor (2025). Real-World Effectiveness and Satisfaction with Risankizumab for the Treatment of Psoriatic Arthritis in Biologic-Naïve Patients: A Population Survey in the United States and Europe. Rheumatology and therapy,
- Mease PJ, Walsh JA, Fitzgerald TP, Chakravarty SD, Adamson E, Emond B, Rossi C, Schwartzbein S, Yokoji K, Wang Y, Lefebvre P, Pilon D, Singla S, Merola J (2025). On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors. Rheumatology and therapy,
- O'Sullivan ML, Cannon GW, Sauer BC, Rojas J, Kunkel GA, Walsh JA, Patel S, Roul P, Baker JF, England BR, Mikuls TR, Braaten T (2025). Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs). Arthritis care & research,
- Mease PJ, Walsh JA, Fitzgerald TP, Chakravarty SD, Adamson E, Emond B, Rossi C, Schwartzbein S, Yokoji K, Wang Y, Lefebvre P, Pilon D, Singla S, Merola J (2025). Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors. Advances in therapy,
- Hernández C, Schlesinger N, Rojas J, Walsh JA, Braaten TJ, Kunkel GA, Jones M, Sauer BC, Facelli J, Cannon GW, Lebiedz-Odrobina (2025). COVID-19 Vaccination is not Associated with the Development of Idiopathic Inflammatory Myositis in U.S. Veterans. Arthritis care & research,
- Mease PJ, Ferrante SA, Shiff NJ, Fitzgerald TP, Chakravarty SD, Walsh J (2025). Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors. Advances in therapy, 42(2), 734-751.
- Carroll C, Aðalsteinsson J, Prouty M, Duffin KC, Krueger GG, Walsh JA, Feng B (2024). Measuring Psoriasis Severity at Home. Journal of visualized experiments, (205),
- Walsh JA, Lin I, Zhao R, Shiff NJ, Morrison L, Emond B, Yu LH, Schwartzbein S, Lefebvre P, Pilon D, Chakravarty SD, Mease (2024). Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous Tumor Necrosis Factor Inhibitors. Drugs - real world outcomes, 11(3), 487-499.
- Nowell WB, Gavigan K, Garza K, O'Beirne R, Safford M, George M, Ogdie A, Walsh JA, Danila MI, Venkatachalam S, Stradford L, Rivera E, Curtis J (2024). Which Educational Topics and Smartphone App Functions Are Prioritized by US Patients With Rheumatic and Musculoskeletal Diseases? A Mixed-Methods Study. The Journal of rheumatology, 51(9), 904-912.
- Deodhar A, Kivitz AJ, Magrey M, Walsh JA, Mease PJ, Greenwald M, Kianifard F, Elam C, Bommidi GM, Winseck A, Gensler L (2024). A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment. Rheumatology (Oxford, England), 64(4), 1864-1872.
- Carroll C, Adalsteinsson JA, Prouty M, Duffin KC, Krueger GG, Walsh JA, Feng B (2024). Erratum: Measuring Psoriasis Severity at Home. Journal of visualized experiments, (213),
- Kristensen LE, Tillett W, Nash P, Coates LC, Mease PJ, Ogdie A, Gisondi P, Ink B, Prickett AR, Bajracharya R, Taieb V, Lyris N, Lambert J, Walsh J (2024). Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies. Therapeutic advances in musculoskeletal disease, 16, 1759720X241288071.
- Navarro-Compán V, Rudwaleit M, Dubreuil M, Magrey M, Marzo-Ortega H, Mease PJ, Walsh JA, Dougados M, de la Loge C, Fleurinck C, Massow U, Vaux T, Taieb V, Deodhar (2024). Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies. The Journal of rheumatology, 52(1), 23-32.
- Patel S, Walsh J, Pinnell D, Pei S, Chen W, Rojas J, Rathod A, Johnson J, Gawron A, Curtis JR, Baker JF, Cannon GW, Wu D, Lai M, Sauer B (2024). Real-world experience with biosimilar infliximab-adba and infliximab-dyyb among infliximab-naïve patients with inflammatory bowel disease in the Veterans Health Administration. Medicine, 103(37), e39476.
- Wang V, Walsh J, Zell J, Verrilli LE, Letourneau J, Johnstone EB, Allen-Brady K, Welt C (2024). Autoimmune Disease is Increased in Women with Primary Ovarian Insufficiency. The Journal of clinical endocrinology and metabolism, 110(8), e2614-2620.
- Baraliakos X, Saffore CD, Collins EB, Parikh B, Ye X, Walsh J (2024). Comparative Efficacy of Advanced Therapies in the Treatment of Radiographic Axial Spondyloarthritis or Ankylosing Spondylitis as Evaluated by the ASDAS Low Disease Activity Criteria. Rheumatology and therapy, 11(4), 989-999.
- Walsh JA, Pei S, Alexander S, Braaten T, Walker JH, Clewell J, Douglas KM, Penmetsa GK, Ye X, Breviu B, Cannon GW, Kunkel GA, Sauer B (2024). Missed opportunities for treatment of inflammatory arthritis and factors associated with non-treatment: An observational cohort study in United States Veterans with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Seminars in arthritis and rheumatism, 66, 152436.
- Gossec L, Walsh JA, Sengupta R, Bushmakin AG, Cappelleri JC, Yndestad A, Dina O, Cella (2024). Improvement of Fatigue in Patients with Ankylosing Spondylitis Receiving Tofacitinib: Analyses of a Phase 3 Randomized Controlled Trial. Rheumatology and therapy, 12(1), 85-98.
- Gossec L, Walsh JA, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Chakravarty SD, Ogdie (2023). Women with Psoriatic Arthritis Experience Higher Disease Burden than Men: Findings from a Real-World Survey in the USA and Europe. The Journal of rheumatology, 50(2), 192-196.
- Walsh JA, Ogdie A, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Dalby CM, Chakravarty SD, Dennis N, Gossec (2023). Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and Europe. Joint bone spine, 90(3), 105534.
- Karmacharya P, Stull C, Stephens-Shields A, Husni ME, Scher JU, Craig E, Fitzsimmons R, Reddy SM, Magrey MN, Ogdie A, Walsh J (2023). Responsiveness and minimal clinically important difference in patient-reported outcome measures among patients with psoriatic arthritis. Arthritis care & research, 75(10), 2182-2189.
- Baraliakos X, Ranza R, Östör A, Ciccia F, Coates LC, Rednic S, Walsh JA, Douglas K, Gao T, Kato K, Song IH, Ganz F, Deodhar (2023). Efficacy of upadacitinib on psoriatic arthritis with axial involvement defined by investigator assessment and pro-based criteria: results from two phase 3 studies . Arthritis research & therapy, 25(1), 56.
- Kiltz U, Kishimoto M, Walsh JA, Sampaio-Barros P, Mittal M, Saffore CD, Wung P, Ganz F, Biljan A, Poddubnyy (2023). Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2. Rheumatology and therapy, 10(4), 887-899.
- Magrey M, Walsh JA, Flierl S, Howard RA, Calheiros RC, Wei D, Khan M (2023). The International Map of Axial Spondyloarthritis Survey: A US Patient Perspective on Diagnosis and Burden of Disease. ACR open rheumatology, 5(5), 264-276.
- Walsh JA, Carroll C, Callis Duffin K, Wang J, Krueger GG, Feng B (2023). PAPRIKA: A Question Bank for Assessing Psoriatic Arthritis Risk in Individuals of Diverse Ancestries. Arthritis care & research, 76(3), 421-425.
- Walsh JA, Saffore CD, Collins EB, Ostor (2023). Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis. Rheumatology and therapy, 10(5), 1385-1398.
- Sen R, Kim E, Napier RJ, Cheng E, Fernandez A, Manning ES, Anderson ER, Maier KD, Hashim M, Kerr GS, Fang MA, Hou JK, Chang E, Walsh JA, Raychadhuri SP, Reimold A, Caplan (2023). Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Biomarkers in Axial Spondyloarthritis: Observational Studies From the Program to Understand the Longterm Outcomes in Spondyloarthritis Registry. Arthritis & rheumatology (Hoboken, N.J.), 75(2), 232-241.
- Karmacharya P, Stull C, Stephens-Shields A, Husni ME, Scher JU, Craig E, Fitzsimmons R, Reddy SM, Magrey MN, Ogdie A, Walsh J (2023). Responsiveness and Minimum Clinically Important Difference in Patient-Reported Outcome Measures Among Patients With Psoriatic Arthritis: A Prospective Cohort Study. Arthritis care & research, 75(10), 2182-2189.
- Walsh JA, Callis Duffin K, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Teeple A, Rowland K, Uy J, McLean RR, Malley W, Cronin A, Merola J (2022). Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry. Dermatology and therapy, 12(1), 97-119.
- Ogdie A, Myers K, Mansfield C, Tillett W, Nash P, Leach C, Nowell WB, Gavigan K, Zueger P, McDearmon-Blondell E, Walsh (2022). Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry. Rheumatology and therapy, 9(2), 735-751.
- Gavigan K, Nowell WB, Hunter T, Curtis JR, Malatestinic WN, Bolce RJ, Lisse JR, Walsh (2022). Employment, Work Productivity, and Biologic Treatments in Self-Reported Axial Spondyloarthritis: a Cross-Sectional Study in a Female Predominant Population from the ArthritisPower Registry. Rheumatology and therapy, 9(2), 663-677.
- van der Horst-Bruinsma IE, de Vlam K, Walsh JA, Bolce R, Hunter T, Sandoval D, Zhu D, Geneus V, Soriano ER, Magrey (2022). Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials. Advances in therapy, 39(6), 2806-2819.
- Walsh JA, Magrey MN, Baraliakos X, Inui K, Weng MY, Lubrano E, van der Heijde D, Boonen A, Gensler LS, Strand V, Braun J, Hunter T, Li X, Zhu B, León L, Calderon DMS, Kiltz (2022). Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial. Arthritis care & research, 74(3), 451-460.
- Gossec L, Walsh JA, Michaud K, Holdsworth E, Peterson S, Meakin S, Yang F, Booth N, Chakravarty SD, Piercy J, Dennis N, Ogdie (2022). Impact of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey. The Journal of rheumatology, 49, 1221-1228.
- Braun J, Kiltz U, Deodhar A, Tomita T, Dougados M, Bolce R, Sandoval D, Lin CY, Walsh (2022). Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. RMD open, 8(2),
- Pizzicato LN, Vadhariya A, Birt J, Ketkar AG, Bolce R, Grabner M, Pepe RS, Walsh J (2022). Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States. Journal of managed care & specialty pharmacy, 29, 1-12.
- Walsh JA, Cai Q, Lin I, Pericone CD, Chakravarty S (2021). Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study. Advances in therapy, 38(5), 2353-2364.
- Ogdie A, Walsh JA, Chakravarty SD, Peterson S, Lo KH, Kim L, Li N, Hsia EC, Chan EKH, Kavanaugh A, Husni M (2021). The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. Clinical rheumatology, 40(9), 3667-3677.
- Orbai AM, Reddy SM, Dennis N, Villacorta R, Peterson S, Mesana L, Chakravarty SD, Lin I, Karyekar CS, Wang Y, Pacou M, Walsh (2021). Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020. Clinical rheumatology, 40(12), 4933-4942.
- Kiltz U, Wei JC, van der Heijde D, van den Bosch F, Walsh JA, Boonen A, Gensler LS, Hunter T, Carlier H, Dong Y, Li X, Bolce R, Strand V, Braun (2021). Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. The Journal of rheumatology, 48(2), 188-197.
- Walsh JA, Pei S, Penmetsa GK, Overbury RS, Clegg DO, Sauer B (2021). Identifying Patients With Axial Spondyloarthritis in Large Datasets: Expanding Possibilities for Observational Research. The Journal of rheumatology, 48(5), 685-692.
- Belman S, Walsh JA, Carroll C, Milliken M, Haaland B, Duffin KC, Krueger GG, Feng B (2021). Psoriasis Characteristics for the Early Detection of Psoriatic Arthritis. The Journal of rheumatology, 48(10), 1559-1565.
- Bekele DI, Cheng E, Reimold A, Geier C, Ganuthula K, Walsh JA, Clegg DO, Dubreuil M, Kaushik P, Ng B, Chang E, Duong R, Park J, Kerr G (2021). Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis. Rheumatology international, 42, 1925-1937.
- Wan MT, Walsh JA, Craig ET, Husni ME, Scher JU, Reddy SM, Leung YY, Ogdie (2021). A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health. Rheumatology (Oxford, England), 60(5), 2307-2316.
- Nowell WB, Gavigan K, Hunter T, Malatestinic WN, Bolce RJ, Lisse JR, Himelein C, Curtis JR, Walsh J (2021). Treatment Satisfaction and Decision-making from the Patient Perspective in Axial Spondyloarthritis: Real-World Data from a Descriptive Cross-sectional Survey Study from the ArthritisPower Registry. ACR open rheumatology, 4, 85-94.
- Nowell WB, Gavigan K, Hunter T, Bolce RJ, Lisse JR, Himelein C, Dubey S, Curtis JR, Walsh J (2021). Patient Perspectives on Biologics for Axial Spondyloarthritis in a Cross-sectional Study in a Predominantly Female Population: Treatment Satisfaction, Wear-off Between Doses, and Use of Supplemental Medication. Rheumatology and therapy, 9, 509-520.
- Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS, COAST-V and COAST-W Study Groups (2020). Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Annals of the rheumatic diseases, 79(2), 176-185.
- Walsh JA, Cai Q, Lin I, Fitzgerald T, Pericone CD, Chakravarty S (2020). Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies. Current medical research and opinion, 36(7), 1245-1252.
- Walsh JA, Pei S, Penmetsa G, Hansen JL, Cannon GW, Clegg DO, Sauer B (2020). Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods. The Journal of rheumatology, 47(1), 42-49.
- Walsh JA, Wan MT, Willinger C, Husni ME, Scher JU, Reddy SM, Ogdie (2020). Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease. The Journal of rheumatology, 47(10), 1496-1505.
- Overbury RS, Pei S, Breviu B, Clegg DO, Walsh J (2020). Obstructive sleep apnea and fatigue in patients with inflammatory arthritis taking TNF-inhibitors. International journal of clinical rheumatology, 15(3), 38.
- Walsh JA, Magrey MN, Baraliakos X, Inui K, Weng MY, Lubrano E, van der Heijde D, Boonen A, Gensler LS, Strand V, Braun J, Hunter T, Li X, Zhu B, León L, Marcelino Sandoval Calderon D, Kiltz (2020). Ixekizumab Improves Functioning and Health in the Treatment of Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results, COAST-X Trial. Arthritis care & research, 74, 451-460.
- Coit P, Kaushik P, Caplan L, Kerr G, Walsh JA, Dubreuil M, Reimold A, Sawalha (2019). Genome-wide DNA methylation analysis in ankylosing spondylitis identifies HLA-B*27 dependent and independent DNA methylation changes in whole blood. Journal of autoimmunity, 102, 126-132.
- Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston (2019). Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis care & research, 71(1), 2-29.
- Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston (2019). Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.), 71(1), 5-32.
- Walsh JA, Pei S, Penmetsa GK, Sauer BC, Patil V, Walker JH, Clewell J, Douglas KM, Clegg DO, Cannon GW, Halwani (2019). Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis. Journal of managed care & specialty pharmacy, 25(11), 1218-1228.
- Mease P, Walsh JA, Baraliakos X, Inman R, de Vlam K, Wei JC, Hunter T, Gallo G, Sandoval D, Zhao F, Dong Y, Bolce R, Marzo-Ortega (2019). Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. Rheumatology and therapy, 6(3), 435-450.
- Deodhar A, Gensler LS, Magrey M, Walsh JA, Winseck A, Grant D, Mease P (2019). Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap. Rheumatology and therapy, 6(4), 487-501.
- Braaten TJ, Zhang C, Presson AP, Breviu B, Clegg DO, Walsh J (2019). Gender Differences in Psoriatic Arthritis with Fatigue, Pain, Function and Work Disability. Journal of psoriasis and psoriatic arthritis, 4(4), 192-197.
- Walsh J, Hunter T, Schroeder K, Sandoval D, Bolce (2019). Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006-2016. BMC rheumatology, 3, 39.
- Farahi JM,Lynn D,Anand P,Walsh JA,Hashim M,Duong R,Dellavalle RP,Reimold A,Kerr GS,Richards JS,Chang E,Kaushik P,Dubreuil M,Caplan (2019). A Prospective Cross-Sectional Analysis of Construct Validity for the PALMPASS, A Brief Patient-Reported Outcome Measure for Psoriasis. Journal of psoriasis and psoriatic arthritis, 4(4), 186-191.
- Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, Gómez-Reino JJ, Aelion JA, ACTIVE investigators (2018). Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Annals of the rheumatic diseases, 77(5), 690-698.
- Walsh JA, Song X, Kim G, Park (2018). Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set. Clinical rheumatology, 37(7), 1869-1878.
- Walsh JA, Gottlieb AB, Hoepken B, Nurminen T, Mease P (2018). Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Clinical rheumatology, 37(12), 3285-3296.
- Walsh JA, Arledge T, Nurminen T, Peterson L, Stark (2018). PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol. The Journal of rheumatology, 45(7), 922-928.
- Walsh JA, Pei S, Burningham Z, Penmetsa G, Cannon GW, Clegg DO, Sauer B (2018). Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance. The Journal of rheumatology, 45(3), 430-436.
- Walsh JA, Pei S, Penmetsa GK, Leng J, Cannon GW, Clegg DO, Sauer B (2018). Cohort identification of axial spondyloarthritis in a large healthcare dataset: current and future methods. BMC musculoskeletal disorders, 19(1), 317.
- Walsh JA, Song X, Kim G, Park (2018). Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set. Journal of pharmaceutical health services research, 9(2), 115-121.
- Walsh JA, Adejoro O, Chastek B, Park (2018). Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. Journal of comparative effectiveness research, 7(4), 369-380.
- Walsh JA, Adejoro O, Chastek B, Palmer JB, Hur (2018). Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses form an Administrative Claims Database . Journal of managed care & specialty pharmacy, 24(7), 623-31.
- Walsh JA, Song X, Kim G, Park (2018). Healthcare Utilization and Direct Costs in Patients with Ankylosing Spondylitis Using a Large US Administrative Claims Database. Rheumatology and therapy, 5(2), 463-474.
- Walsh JA, Jones H, Mallbris L, Duffin KC, Krueger GG, Clegg DO, Szumski (2018). The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA. Psoriasis (Auckland, N.Z.), 8, 65-74.
- Walsh JA, Song X, Kim G, Park Y (2018). Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set. Journal of cardiology and cardiovascular sciences, 2(6), 17-23.
- van der Heijde D, Dougados M, Landewé R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar (2017). Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford, England), 56(9), 1498-1509.
- Walsh JA, Shao Y, Leng J, He T, Teng CC, Redd D, Treitler Zeng Q, Burningham Z, Clegg DO, Sauer B (2017). Identifying Axial Spondyloarthritis in Electronic Medical Records of US Veterans. Arthritis care & research, 69(9), 1414-1420.
- Walsh JA, Tan H, Valdez H, Callis Duffin (2017). Comparative Assessment of PASI and Variations of PGA×BSA as Measures of Psoriasis Severity. Journal of psoriasis and psoriatic arthritis, 2(4), 113-118.
- Sauer BC, Teng CC, He T, Leng J, Lu CC, Walsh JA, Shah N, Harrison DJ, Tang DH, Cannon G (2016). Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis. Journal of medical economics, 19(1), 34-43.
- Walsh JA, Zhou X, Clegg DO, Teng C, Cannon GW, Sauer (2015). Mortality in American Veterans with the HLA-B27 gene. The Journal of rheumatology, 42(4), 638-44.
- Sieper J, Landewé R, Rudwaleit M, van der Heijde D, Dougados M, Mease PJ, Braun J, Deodhar A, Kivitz A, Walsh J, Hoepken B, Nurminen T, Maksymowych W (2015). Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. Arthritis & rheumatology (Hoboken, N.J.), 67(3), 668-77.
- Walsh JA, McFadden ML, Morgan MD, Sawitzke AD, Duffin KC, Krueger GG, Clegg D (2014). Work productivity loss and fatigue in psoriatic arthritis. The Journal of rheumatology, 41(8), 1670-4.
- Coates LC, Walsh J, Haroon M, FitzGerald O, Aslam T, Al Balushi F, Burden AD, Burden-Teh E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell P (2014). Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools. Arthritis care & research, 66(9), 1410-6.
- Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, McHugh N, Mease PJ, Strand V, Waxman R, Azevedo VF, Beltran Ostos A, Carneiro S, Cauli A, Espinoza LR, Flynn JA, Hassan N, Healy P, Kerzberg EM, Lee YJ, Lubrano E, Marchesoni A, Marzo-Ortega H, Porru G, Moreta EG, Nash P, Raffayova H, Ranza R, Raychaudhuri SP, Roussou E, Scarpa R, Song YW, Soriano ER, Tak PP, Ujfalussy I, de Vlam K, Walsh J (2013). The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Annals of the rheumatic diseases, 72(6), 986-91.
- Walsh JA, McFadden M, Woodcock J, Clegg DO, Helliwell P, Dommasch E, Gelfand JM, Krueger GG, Duffin K (2013). Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. Journal of the American Academy of Dermatology, 69(6), 931-7.
- Walsh JA, Callis Duffin K, Krueger GG, Clegg D (2013). Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. The Journal of rheumatology, 40(3), 287-93.
- Walsh JA, Duffin KC, Crim J, Clegg D (2012). Lower frequency of obstructive sleep apnea in spondyloarthritis patients taking TNF-inhibitors. Journal of clinical sleep medicine, 8(6), 643-8.
- Zamboni WC, Houghton PJ, Hulstein JL, Kirstein M, Walsh J, Cheshire PJ, Hanna SK, Danks MK, Stewart C (1999). Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer chemotherapy and pharmacology, 43(4), 269-76.
Review
- Walsh JA, Magrey (2021). Clinical Manifestations and Diagnosis of Axial Spondyloarthritis. Journal of clinical rheumatology, 27(8), e547-e560.
- Magrey MN, Danve AS, Ermann J, Walsh J (2020). Recognizing Axial Spondyloarthritis: A Guide for Primary Care. Mayo Clinic proceedings, 95(11), 2499-2508.
- Walsh JA, Rozycki M, Yi E, Park (2019). Application of machine learning in the diagnosis of axial spondyloarthritis. Current opinion in rheumatology, 31(4), 362-367.
- Walsh JA, Song X, Kim G, Park Y (2019). Counting the Costs of Ankylosing Spondylitis. Research Outreach, 2517(106), 82-85.
- Boehncke WH, Qureshi A, Merola JF, Thaçi D, Krueger GG, Walsh J, Kim N, Gottlieb A (2014). Diagnosing and treating psoriatic arthritis: an update. The British journal of dermatology, 170(4), 772-86.
Conference Proceedings
- Haberman R, Perez-Chada LM, Siegel E, Reginato AM, Webster D, Chandran V, Walsh J, Rosen CF, Reddy S, Ogdie A, Scher JU, Merola J (2020). Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2018 Annual Meeting Summary. Rheumatology international, 5(2), 68-72.
Case Report
- Jones BB, Millsop JW, Walsh JA, Krueger GG, Callis Duffin (2015). Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients. The British journal of dermatology, 173(1), 272-4.
- Kinard K,Walsh JA,Penmetsa GK,Warner JE (2014). Adalimumab and non-arteritic anterior ischaemic optic neuropathy: A case report. Neuro-ophthalmology (Aeolus Press), 38(5), 272-277.
Abstract
- Ostor A, Walsh J, Saffore C, Ye X, Patel M, Biljan A, Vora J, Truman I, Edwards M, Milligan G, Tillett (2025). Real-World Effectiveness and Satisfaction in Biologic-Naïve Patients With Psoriatic Arthritis and Limited Joint Involvement Treated With Risankizumab in the United States and Europe. 77(Suppl 9),
- Ogdie A, Middaugh N, Marchese M, Walsh J, Bello N, Lisse J, Kronbergs A, Grace E, Ngantcha M, Mease (2024). Cycling to TNFi versus switching to IL17Ai after a first TNFi discontinuation among patients with PsA and axSpA: The CorEvitas PsA/SpA Registry. 76(Suppl 9),
- Tillett W, Gladman D, Gossec L, Eells J, Healy P, Ink B, Lyris N, Walsh J (2024). Achieving Stringent Disease Control Criteria Was Associated with Greater Work Productivity Improvements in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab. 76(Suppl 9),
- Allsop V, Glasheen B, Khong S, Minjarez A, Morlan N, Roake K, Cannon g, Grant N, Walsh J (2024). Education and Medication Access Needs in Rheumatology Patients Starting New Medications: Quality Improvement Data from a Pharmacist Intervention [abstract]. . 76(Suppl 9),
- Mease P, Zhao R, Ferrante S, Shiff N, Srinivas P, Chakravarty S, Walsh J (2024). Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous IL-17A Inhibitors. 76(Suppl 9),
- Alexander S, Pei S, Penmetsa G, Reddy S, Scher J, Ogdie A, Walsh J (2024). Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Appropriateness of Rheumatology Referrals and Treatment Outcomes. 76(Suppl 9),
- Loftis C, Caplan L, Padilla Zepeda J, Mukooba N, Caplan M, Fang M, Stolyar L, Walsh J, Kerr G, Raychaudhuri S, Reimold A, Wong M (2024). Race and Ethnicity as Predictors of Diagnostic Delay in Psoriatic Arthritis and Axial Spondyloarthritis. 76(Suppl 9),
- O'Sullivan M, Cannon g, brian S, Rojas J, Kunkel G, Walsh J, Roul P, Patel s, Baker J, England B, Braaten T (2024). Underlying Autoimmune Disease Has Not Limited Immune Checkpoint Inhibitor Use or Increased Mortality Risk During Cancer Treatment of US Veterans . 76(Suppl 9),
- Walsh J, Merola J, Ritchlin C, Tanaka Y, Favalli E, McGonagle D, Thaçi D, Ink B, Bajracharya R, Coarse J, Tillett W (2024). Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies. 76(Suppl 9),
- Walsh J, Pei S, Penmetsa G, Alexander S, Ly N, Molano-Romero R, Conlon A, Bakewell C, Reddy S, Scher J, Ogdie A (2024). Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Diagnosis Rates, Referral Pathways, and Educational Value of Screening. 76(Suppl 9),
- Kristensen LE, Coates L, Mease PJ, Merola JF, Gisondi P, Nash P, Orbai AM, Tillett W, Ink B, Bajracharya R, Taieb V, Lambert J, Willems D, Walsh J (2023). Achievement of increasingly stringent clinical disease control criteria was associated with greater improvements in physical function, pain and fatigue in patients with active psoriatic arthritis: 52-week results from Be Optimal, a phase 3 randomised, placebo-controlled study. 82(Suppl 1), 1776.
- Gossec L, Cella D, Walsh JA, Sengupta R, Bushmakin AG, Cappelleri JC, Yndestad A, Dina (2023). Time to improvement of fatigue in patients with ankylosing spondylitis in a study of tofacitinib. 81(Suppl 1), 401.
- Magrey M, Walsh JA, Flierl S, Calheiros R, Wei D, Khan M (2023). The International Map of Axial Spondyloarthritis (IMAS): a US patient perspective on diagnosis and burden of disease. 81(Suppl 1), 1521.
- Penmetsa GK, Pei S, Sauer BC, Douglas K, Walker J, Clewell J, Feng B, Walsh J (2021). Identifying Erosive Disease from Radiology Reports of Veterans with Inflammatory Arthritis with Natural Language Processing. 73(suppl 10),
- Hernandez C, Schlesinger N, Rojas J, Walsh J, Braaten T, Kunkel G, Jones M, brian S, Facelli J, Cannon g, Lebiedz-Odrobina D The Risk for Development of Myositis Is Not Increased After COVID-19 Vaccination Among U.S. Veterans. 76(Suppl 9),
If you have, or think you have ankylosing spondylitis, this is the doctor you should consult.
If you are lucky enough to see Dr. Walsh, you will be treated with respect and compassion. She knows her field and has the added component of empathy. Dr. Walsh is very good at looking through past lab work and visits to make sure she does not miss anything important. She is also a good listener and values the patient's opinion.
Very professional and smart as a whip.
Dr Walsh has helped me in many ways. When I first started seeing her she gave me hope about my health and proceeded to help me to get healthier and able to start moving and living again. All of my follow up visits have been the same. Always being helpful and concerned for my well being. I appreciate her Knowledge and all her efforts concerning my health. I would recommend her to All who might need her expertise.
Excellent doctor, have been with her many years
Dr Walsh is excellent to work with. I HIGHLY recommend her.
She is very friendly and has a great sense of humor.
Dr. Walsh is a superlative rheumatologist!
She is great. She listens and cares.
Dr Walsh has given me great care and advice.
She has always provided me with positive results.
I really appreciated her thoroughness and willingness to spend the time to understand everything that was going on with my health. I really appreciated it!!!
Dr. Walsh is an excellent physician, she has communicated very clearly and makes sure I understand my options. Her expertise and leadership in developing the specialty clinic at U of U Rheumatology adds a great deal of value to our healthcare community.
Dr. Walsh, and the others in the office, were great. Answered all my questions and took time to listen to my concerns.
Dr Walsh is an outstanding and caring physician. I have been seeing her for 15 years
Jessica really cares about her patients and their health needs, she is always thinking of things that might help my physical conditions
Dr. Walsh is amazing! Her communication skills are top notch. She makes you feel comfortable talking about your concerns and ideas. Her bedside manner and support for her patients is second to none.
Awesome
Best MD. I have had in Rheumatology
Dr Walsh made my decisions easier to make. After being informed I now know what to expect and how important my decisions are. I now understand why. Thank you Dr Walsh.
Excellent physician!
Thank you Dr Walsh for being caring and kind. And for spending extra time with our patient, your recommendations and great info you provided us!
Dr Walsh is amazing. She is very , lets me participate in my care, she is amazing.
I would recommend that you give Dr. Walsh a chance to help you feel better and do better. I think you would be amazed to know how wonderful it is to go to a referral center and help people that specialize only in one area, and treat that area that you're affected with, with the latest and best care that's available. You're worth it.
She is the best Dr I've ever seen to treat my Psoriatic arthritis. She's thorough, addresses every issue I have, everytime, and tries to help find a doable solution. I absolutley Love Dr Walsh. She is so good that she's next to impossible to get an appointment with.
As I said, Dr. Walsh treats the whole patient. She remembers things about me and my life, and she watches for ways or treatments that may improve my life. I think she is an excellent doctor!
Dr Walsh is a very caring Dr. I feel that she really listens to my challenges and works to find the best resolutions, including me in all options, and we decide together which things to utilize in finding the best things to help me.
Dr. Jessica Walsh is absolutely a Class Act. She spent so much personal time with me. She educates me each time we see each other. I trust her with my life and she's pulled me through some tough times. She truly is wonderful and very thorough.
The The assistant was very nice and she she explained everything to me so I can understand.
Very professional and pleasant. Thanks for your kind attention.
Dr Walsh is the best! She listens to my concerns and addresses them directly. She monitors my symptoms and helps me deal with them. Can you hire more doctors like her?
Dr Walsh is amazingly talented and focused on the role of my care. She has helped me more than I can ever say. Thank you for your dedication to your profession.
She is the BEST in the business. She gives Healthcare a good name in a day and age when others don't. She is so knowledgeable, yet takes time and listens to me. I do not know what I would do with my medical problems if it were not for her and her staff!
Dr. Walsh is my favorite dr. So caring and listens to me. She personifies what every dr should be. Great bedside manners, yet is very efficient.
Dr. Walsh is an impressive physician who is highly experienced and has great compassion for her patients. She has become my most treasured health care provider!
She is the best Doctor in Utah.
Professional, knowledgeable, personable
Dr Walsh is very attentive, knowledgeable, helpful working with me to handle an unusual issue with my treatment. She is empathetic and compassionate. I feel confident knowing she is my doctor.
I have been a patient of Dr. Walsh for several years. Her excellent analysis and treatment of my condition has greatly improved my quality of life.
She is very good and easy to work with. I could not get the circles marked.
Always compassionate , caring, and knowledgeable -
She is very caring, and extremely thorough. She listens and asks questions that are thought out and pertinent to me. I am so glad this department reached out to me since I m at risk for psoriatic arthritis and because of that and the results of the imaging and tests she ordered, I am not ignoring symptoms I've had and getting help.
She is very caring of my conditions and is looking for solutions to solve them, but she talks it all through with me as how we should proceed so I trust her call.
Best Doctor ever!
Very nice and respectful.
she really cares about her patients and is very kind, helpfull, knowledgable and always has good recommendations for improvements. great doctor, she is the best!!
An extremely concerned doctor that wanted me to be involved in my care.
Jessica is clearly very knowledgeable, is a great listener and answers your questions clearly. She cares. I highly recommend her.
Successful. Thank you
Very knowledgeable but spread too thin.
Excellent good communication so that I understood
I have had the good fortune to have been Dr Walsh's patient for several years and she took me back after my 2.5 year stay in California. I trust her completely and feel fortunate to have her expertise available.
Dr. Walsh listened to my concerns and addressed each one of them. I felt respected and well cared for. She is a thoughtful and kind physician.
Taking this survey is useless!
I had a much better experience with Dr Walsh, Dr Krutko, and their teams than another provider at UH rheumatology. I felt like I was a part of the decision making process. I felt that they had a genuine concern in accurately identifying what the issue was. Everything was explained clearly and concisely.
Not sure. It was a tough travel for 2 70 year olds to travel four hours one way to be told wait until October, don't take your infusions and we will see what happens. So far I am not feeling good about my experience. If I don't hear anything back from the doctor soon about my scans and blood tests then our trip will be bad and probably not worth the travel from Idaho Falls to SLC.
Dr. Walsh is the best rheumatologist I've ever seen.
We had to work together to go over my last appointment. I also had more health concerns outside of her field. She was very sympathetic and we were able to work out some questions I had. She was actually pretty amazing.
Dr. Walsh is one of the best things that has ever happened to me in the 30 years I have been suffering with PsA. She is knowledgeable and has made suggestions that have made my arthritis totally tolerable. I have been coming to Dr. Walsh since 2018 - I wish I had found her years ago! Where has she been all my life??
Dr Walsh listens carefully to me. She makes me feel like I'm part of the team and we are all working together yo improve my life. She is also a superb diagnostician.
Doctor was just a bit rushed it seemed. She did explain side effects and we did talk about going back to enbrel or starting a new one and we picked the new one, I felt more comfortable in her choice of that, due to her experience and history as a doctor specializing in my condition. Not a lot of eye contact but it was virtual and awkward for us both. She did ask me which way I would like to go with a medication. I just didn't have a lot of questions or more specific I was scared to ask them due to my social anxiety.
She is an excellent physician. She gives me great care.
Dr. Walsh always provides exemplary care
We had a lot of difficult crap to get through this day. It was extremely emotional. Dr Walsh was enormously empathetic
Dr. Walsh is excellent and is always attentive. She advises and listens. She remembers what you have discussed on previous visits. She is excellent.
Dr. Walsh sets the bar high for her kindness and interest in making me feel importsnt
As always - Dr Walsh is exemplary.
The doctor is very thorough. She seems to explore all treatment options. She changes my care to take advantage of all possible treatments.
I drive from Idaho to my appointments. Dr. Walsh and I had a very good conversation about by issues and discussed a plan to figure it out
Dr. Walsh defines the ideal physician. I am so fortunate to have had her as my rheumatologist since 2018. She sees the whole picture. She listens to my concerns, makes excellent care recommendations and my arthritic condition is so much better because of her direction. I have total faith in her.
excellent Doctor Who answered all questions.
Dr. Walsh is the best position in the industry, hands down. I am so lucky to have found her My health is improved, and actually my mind set has as well
Mentioned earlier. Visit limited to a conventional phone call
Dr. Jessica Walsh is a wonderful person. She spend time explained my questions. I am really appreciated her knowledge and her professionalism.
Great as always.
I very much appreciate these providers.
Dr. Walsh is the consummate professional. I feel very fortunate to have her as my doctor.
Doctor Walsh is simply the best in the business. Her knowledge, skills and expertise has saved the day for me on so many levels. I was on a biologic for my PsA, and when I retired, I lost the Enbrel that has been helping me for over 19 years. Dr. Walsh found that Remicade would be paid for by Medicare and I am doing so well.
Dr Walsh is patient and decisive. I enjoy my appointments with her.
Dr Walsh is EXCELLENT
Dr. Walsh is a sincere professional. I always feel she is concerned about my condition.
Absolutely exceptional. The doctor spent an extended period of time with me going through all my questions without ever seeming rushed or bothered. Very rare to meet a doctor with such an exceptional patience and respect for her patients.
Love Dr Walsh!
Anyone who has a problem with Doctor Walsh is crazy
I went in for a fresh discussion of my symptoms and she relied heavily on the tests from the previous doctor I went to. Doctor appointment was discussed at length only on previous tests. we didn't discuss osteoarthritis at all. I should have asked more on this. Doctor did prescribe pain gel which is good. In all, I wanted to know more about why I am having so much pain.
I am not kidding. Dr. Walsh is the best. My disease, psoriatic arthritis, is scarier than heck. She takes the time to listen to my symptoms, make suggestions and explain the myriad of lab work I have to have done. Whenever I visit with her, I feel like I am the only patient in the world, even when I know that is not true
good listener
great experience if you like the virtual world
outstanding providers. I was very impressed. Dr. Walsh and her fellow were extraordinary, caring, detail oriented, attentive. true experts. wow!!!
Poor care. Doesn't know what's going on.
very professional and knowledgeable!
I get great care from Dr. Walsh